Zacks: ProNAi Therapeutics Inc. (DNAI) Receives Average Rating of “Hold” from Brokerages
Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) have received an average broker rating score of 3.00 (Hold) from the three brokers that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a hold recommendation. ProNAi Therapeutics’ rating score has declined by 20% in the last three months as a result of various analysts’ ratings changes.
Analysts have set a one year consensus price target of $2.50 for the company and are predicting that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also given ProNAi Therapeutics an industry rank of 109 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 15th.
Shares of ProNAi Therapeutics (NASDAQ:DNAI) opened at 1.80 on Thursday. The firm’s market capitalization is $54.59 million. ProNAi Therapeutics has a one year low of $1.77 and a one year high of $20.85. The stock’s 50 day moving average price is $1.85 and its 200 day moving average price is $3.31.
ProNAi Therapeutics (NASDAQ:DNAI) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.05. Analysts expect that ProNAi Therapeutics will post ($1.32) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in DNAI. Vivo Capital LLC bought a new stake in ProNAi Therapeutics during the first quarter worth approximately $16,434,000. Deerfield Management Co. increased its stake in ProNAi Therapeutics by 67.6% in the first quarter. Deerfield Management Co. now owns 3,001,302 shares of the company’s stock worth $20,229,000 after buying an additional 1,210,047 shares in the last quarter. Pictet Asset Management Ltd. increased its stake in ProNAi Therapeutics by 957.9% in the second quarter. Pictet Asset Management Ltd. now owns 684,433 shares of the company’s stock worth $4,298,000 after buying an additional 619,733 shares in the last quarter. Sabby Management LLC bought a new stake in ProNAi Therapeutics during the second quarter worth approximately $1,174,000. Finally, Minerva Advisors LLC bought a new stake in ProNAi Therapeutics during the second quarter worth approximately $227,000. Institutional investors and hedge funds own 35.25% of the company’s stock.
About ProNAi Therapeutics
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.